Vidal Crespo, Anna (Date of defense: 2017-04-28)
In this thesis we have focused on two novel therapeutic strategies that target the crosstalk between the tumor cells and the microenvironment. Chronic lymphocytic leukemia (CLL) remains an incurable ...
Rosich Moya, Laia (Date of defense: 2014-06-05)
La via de supervivència PI3K/AKT/mTOR es troba constitutivament activada en molts tumors, fet que ha afavorit el desenvolupament de nombrosos inhibidors al considerar-se una possible opció terapèutica. ...
Llorente Lope, Alicia (Date of defense: 2021-03-23)
Metastatic breast cancer (BCa) is the leading cause of death in BCa patients. Current therapies for BCa aim at cell proliferation and, therefore, latent disseminated cells are able to escape treatment. ...
Rijo Mora, Enrique Antonio (Date of defense: 2017-09-26)
INTRODUCCIÓN: MICA (Major histocompatibility complex I Chain related proteins to gen A) se expresa como respuesta al estrés celular en procesos neoplásicos, inflamatorios, infecciones virales y ...
Muñoz Almendros, Clara (Date of defense: 2013-11-08)
Los tumores germinales testiculares (TCGT) son una neoplasia poco frecuente, ya que sólo representa alrededor del 2% de los cánceres que afectan al varón. Sin embargo, son el tumor más frecuente en ...
Hardy-Werbin, Max (Date of defense: 2020-01-30)
El cáncer de pulmón de célula pequeña (CPCP) es el subtipo mas agresivo del cáncer de pulmón. Mas de la mitad de los pacientes se diagnostican con enfermedad diseminada, donde el tratamiento de elección ...
Benítez, Sandra (Date of defense: 2021-01-13)
Receptor activator of nuclear factor kappa-β ligand (RANKL) and its receptor RANK are key mediators of bone resorption1,2. RANKL, its receptor RANK and its natural decoy receptor OPG, which is a competitive ...
Noguera-Castells, Aleix (Date of defense: 2022-01-31)
Modern oncology conceives solid tumours as organs by themselves, meaning that not only should the behaviour of cancer cells to be considered and evaluated therapeutically, but also the so-called tumour ...
Manzano Muñoz, Albert (Date of defense: 2022-12-15)
[eng] Personalized medicine has emerged to improve cancer treatment beyond classical approaches. The identification of genetic mutations by molecular analyses dominate personalized medicine initiatives ...
Fernández Plana, Julen (Date of defense: 2019-01-09)
El tractament de quimioteràpia associada a fàrmacs anti-EGFR representa un estàndard de tractament oncològic per a un subgrup de pacients amb Càncer colorectal metastàtic (CCRm). Malgrat això, no tots ...